This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sudhir, K. Search for Related Content PubMed PubMed Citation Articles by Sudhir, K. Related Collections Lipid Cardiovascular Endocrinology Metabolism

Lipoprotein-Associated Phospholipase A₂, a Novel Inflammatory Biomarker and Independent Risk Predictor for Cardiovascular Disease

Cardiovascular Core Analysis Laboratory, Stanford University Medical Center, Stanford, California 94305

Address all correspondence and requests for reprints to: Dr. Krishnankutty Sudhir, Room H3554, Cardiovascular Core Analysis Laboratory, Stanford University Medical Center, Stanford, California 94305-5637. E-mail: ksudhir{at}cvmed.stanford.edu.

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) is a member of the phospholipase A₂ superfamily, a family of enzymes that hydrolyze phospholipids. Circulating Lp-PLA₂ is a marker of inflammation that plays a critical role in atherogenesis; its inhibition may have antiatherogenic effects. Epidemiological data have consistently demonstrated the association of increased levels of Lp-PLA₂ with increased risk of coronary heart disease (CHD). In general, studies from the West of Scotland Coronary Prevention Study, Monitoring Trends and Determinants in Cardiovascular Diseases, and Rotterdam cohorts have shown that the association of Lp-PLA₂ with CHD is not attenuated upon multivariate analysis with traditional risk factors and other inflammatory markers. In addition, in the Atherosclerosis Risk in Communities cohort, Lp-PLA₂ was particularly useful in identifying CHD risk among patients with a baseline low-density lipoprotein less than 130 mg/dl. Studies in subjects with coronary artery disease have also shown associations between Lp-PLA₂ and cardiovascular risk. Polymorphisms of the Lp-PLA₂ gene have been reported, with varying significance, in Japanese and Caucasian populations. Overall, epidemiological studies suggest that measurement of Lp-PLA₂ in plasma may be useful in identifying individuals at high risk for cardiac events.

This article has been cited by other articles:

				J. P. Corsetti, D. Ryan, A. J. Moss, D. L. Rainwater, W. Zareba, and C. E. Sparks Glycoprotein Ib{alpha} Polymorphism T145M, Elevated Lipoprotein-Associated Phospholipase A2, and Hypertriglyceridemia Predict Risk for Recurrent Coronary Events in Diabetic Postinfarction Patients Diabetes, May 1, 2007; 56(5): 1429 - 1435. [Abstract] [Full Text] [PDF]

				C. A. Garza, V. M. Montori, J. P. McConnell, V. K. Somers, I. J. Kullo, and F. Lopez-Jimenez Association Between Lipoprotein-Associated Phospholipase A2 and Cardiovascular Disease: A Systematic Review Mayo Clin. Proc., February 1, 2007; 82(2): 159 - 165. [Abstract] [Full Text] [PDF]

				Y. Jang, O. Y. Kim, S. J. Koh, J. S. Chae, Y. G. Ko, J. Y. Kim, H. Cho, T.-S. Jeong, W. S. Lee, J. M. Ordovas, et al. The Val279Phe Variant of the Lipoprotein-Associated Phospholipase A2 Gene Is Associated with Catalytic Activities and Cardiovascular Disease in Korean Men J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3521 - 3527. [Abstract] [Full Text] [PDF]

				J. P. Corsetti, D. L. Rainwater, A. J. Moss, W. Zareba, and C. E. Sparks High Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Recurrent Coronary Events in Postinfarction Patients Clin. Chem., July 1, 2006; 52(7): 1331 - 1338. [Abstract] [Full Text] [PDF]